Microneedle and mucosal delivery of influenza vaccines

References

• Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur. Respir. J. 17(6), 1282–1293 (2001).
   PubMed Web of Science ®Google Scholar
• Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171(10), 4969–4973 (2003).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: past, present and future. Nat. Med. 11(4 Suppl.), S5–S11 (2005).
   PubMed Web of Science ®Google Scholar
• Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull. World Health Organ. 77(10), 801–807 (1999).
   PubMed Web of Science ®Google Scholar
• Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 19(1), 95–103 (2004).
   PubMed Web of Science ®Google Scholar
• Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am. J. Trop. Med. Hyg. 68(3), 341–344 (2003).
   PubMed Web of Science ®Google Scholar
• Breau LM, McGrath PJ, Craig KD, Santor D, Cassidy KL, Reid GJ. Facial expression of children receiving immunizations: a principal components analysis of the child facial coding system. Clin. J. Pain 17(2), 178–186 (2001).
   PubMed Web of Science ®Google Scholar
• Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26(26), 3197–3208 (2008).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4(3), 211–222 (2004).
   PubMed Web of Science ®Google Scholar
• McKenzie R, Bourgeois AL, Frech SA et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25(18), 3684–3691 (2007).
   PubMed Web of Science ®Google Scholar
• Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24(35–36), 6110–6119 (2006).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6(12), 1403–1406 (2000).
   PubMed Web of Science ®Google Scholar
• Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. Acceptance of Intanza® 9 µg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv. Ther. 28(8), 640–649 (2011).
   PubMed Web of Science ®Google Scholar
• Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 103(1–2), 177–185 (2004).
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369–393 (2009).
   PubMedGoogle Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261–1268 (2008).
   PubMed Web of Science ®Google Scholar
• Birchall J, Coulman S, Pearton M et al. Cutaneous DNA delivery and gene expression in ex vivo human skin explants via wet-etch micro-fabricated micro-needles. J. Drug Target. 13(7), 415–421 (2005).
   PubMed Web of Science ®Google Scholar
• Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J. Control. Release 104(1), 51–66 (2005).
   PubMed Web of Science ®Google Scholar
• Pearton M, Allender C, Brain K et al. Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations. Pharm. Res. 25(2), 407–416 (2008).
   PubMed Web of Science ®Google Scholar
• Dean CH, Alarcon JB, Waterston AM et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum. Vaccin. 1(3), 106–111 (2005).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Dekker JP 3rd, Harvey NG et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74(12), 6806–6810 (2006).
   PubMed Web of Science ®Google Scholar
• Prausnitz MR. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56(5), 581–587 (2004).
   PubMed Web of Science ®Google Scholar
• Widera G, Johnson J, Kim L et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 24(10), 1653–1664 (2006).
   PubMed Web of Science ®Google Scholar
• Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J. Control. Release 117(2), 227–237 (2007).
   PubMed Web of Science ®Google Scholar
• Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharm. Res. 24(7), 1369–1380 (2007).
   PubMed Web of Science ®Google Scholar
• Pearton M, Kang SM, Song JM et al. Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines. PLoS ONE 5(8), e12410 (2010).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25(10), 1814–1823 (2007).
   PubMed Web of Science ®Google Scholar
• Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials 29(13), 2113–2124 (2008).
   PubMed Web of Science ®Google Scholar
• Park JH, Allen MG, Prausnitz MR. Polymer microneedles for controlled-release drug delivery. Pharm. Res. 23(5), 1008–1019 (2006).
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, Del Pilar Martin M et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16(8), 915–920 (2010).
   PubMed Web of Science ®Google Scholar
• Birchall JC. Microneedle array technology: the time is right but is the science ready? Expert Rev. Med. Devices 3(1), 1–4 (2006).
   PubMed Web of Science ®Google Scholar
• Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 17(4), 187–207 (2010).
   PubMed Web of Science ®Google Scholar
• Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin. Vaccine Immunol. 14(4), 375–381 (2007).
   PubMed Web of Science ®Google Scholar
• Atmar RL, Patel SM, Keitel WA. Intanza®: a new intradermal vaccine for seasonal influenza. Expert Rev. Vaccines 9(12), 1399–1409 (2010).
   PubMed Web of Science ®Google Scholar
• Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25(52), 8833–8842 (2007).
   PubMed Web of Science ®Google Scholar
• Laurent PE, Pettis R, Easterbrook W, Berube J. Evaluating new hypodermic and intradermal injection devices. Med. Device Technol. 17(2), 16–19 (2006).
   PubMedGoogle Scholar
• Duggan ST, Plosker GL. Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged > or =60 years). Drugs Aging 27(7), 597–605 (2010).
   PubMed Web of Science ®Google Scholar
• Falsey AR. New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine 28(Suppl. 4), D24–D32 (2010).
   PubMed Web of Science ®Google Scholar
• Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 7, 13 (2009).
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650–658 (2008).
   PubMed Web of Science ®Google Scholar
• Coudeville L, Andre P, Bailleux F, Weber F, Plotkin S. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum. Vaccin. 6(10), 841–848 (2010).
   PubMed Web of Science ®Google Scholar
• Arnou R, Icardi G, De Decker M et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter Phase III study. Vaccine 27(52), 7304–7312 (2009).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Arnou R, Kafeja F et al. Evaluation of noninferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect. Dis. 10, 134 (2010).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take? J. Infect. Dis. 198(5), 632–634 (2008).
   PubMed Web of Science ®Google Scholar
• Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 119(6), 1076–1082 (2007).
   PubMed Web of Science ®Google Scholar
• Laurent A, Mistretta F, Bottigioli D et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 25(34), 6423–6430 (2007).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Wilkins K et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25(37–38), 6755–6763 (2007).
   PubMed Web of Science ®Google Scholar
• Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin. Infect. Dis. 50(10), 1331–1338 (2010).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27(3), 454–459 (2009).
   PubMed Web of Science ®Google Scholar
• Sugimura T, Ito Y, Tananari Y et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 26(22), 2700–2705 (2008).
   PubMed Web of Science ®Google Scholar
• Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25(4), 659–663 (2007).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351(22), 2295–2301 (2004).
   PubMed Web of Science ®Google Scholar
• La Montagne JR, Fauci AS. Intradermal influenza vaccination – can less be more? N. Engl. J. Med. 351(22), 2330–2332 (2004).
   PubMed Web of Science ®Google Scholar
• Langley JM. Intradermal injection of reduced-dose influenza vaccine was immunogenic in young adults. ACP J. Club 142(3), 68–69 (2005).
   Google Scholar
• Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines 7(8), 1201–1214 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zarnitsyn VG, Ye L et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl Acad. Sci. USA 106(19), 7968–7973 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 27(49), 6932–6938 (2009).
   PubMed Web of Science ®Google Scholar
• Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 4(3), e4773 (2009).
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS ONE 4(9), e7152 (2009).
   PubMed Web of Science ®Google Scholar
• Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 25(6), 1256–1273 (2008).
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J. Control. Release 147(3), 326–332 (2010).
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 11(3), 1193–1201 (2010).
   PubMed Web of Science ®Google Scholar
• Song JM, Kim YC, Barlow PG et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res. 88(2), 244–247 (2010).
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Vunnava A et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J. Virol. 84(15), 7760–7769 (2010).
   PubMed Web of Science ®Google Scholar
• Song JM, Kim YC, Lipatov AS et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin. Vaccine Immunol. 17(9), 1381–1389 (2010).
   PubMed Web of Science ®Google Scholar
• Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J. Infect. Dis. 204(4), 582–591 (2011).
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J. Infect. Dis. 201(2), 190–198 (2010).
   PubMed Web of Science ®Google Scholar
• De Becker G, Sornasse T, Nabavi N et al. Immunoglobulin isotype regulation by antigen-presenting cells in vivo. Eur. J. Immunol. 24(7), 1523–1528 (1994).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113(7), 998–1007 (2004).
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77(9), 5218–5225 (2003).
   PubMed Web of Science ®Google Scholar
• Hon H, Jacob J. Tracking dendritic cells in vivo: insights into DC biology and function. Immunol. Res. 29(1–3), 69–80 (2004).
   PubMed Web of Science ®Google Scholar
• Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res. 143(2), 140–146 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J. Control. Release 142(2), 187–195 (2010).
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm. Res. 28(1), 135–144 (2011).
   PubMed Web of Science ®Google Scholar
• Maa YF, Ameri M, Shu C, Payne LG, Chen D. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J. Pharm. Sci. 93(7), 1912–1923 (2004).
   PubMed Web of Science ®Google Scholar
• Amorij JP, Meulenaar J, Hinrichs WL et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25(35), 6447–6457 (2007).
   PubMed Web of Science ®Google Scholar
• Chen D, Endres RL, Erickson CA et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med. 6(10), 1187–1190 (2000).
   PubMed Web of Science ®Google Scholar
• Chen D, Weis KF, Chu Q et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J. Virol. 75(23), 11630–11640 (2001).
   PubMed Web of Science ®Google Scholar
• Chen D, Periwal SB, Larrivee K et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol. 75(17), 7956–7965 (2001).
   PubMed Web of Science ®Google Scholar
• Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine 23(5), 681–686 (2004).
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148–158 (2006).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Baekkevold ES, Farstad IN et al. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol. Today 20(3), 141–151 (1999).
   PubMedGoogle Scholar
• Modlin JF, Onorato IM, McBean AM et al. The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral poliovirus vaccine. Am. J. Dis. Child. 144(4), 480–484 (1990).
   PubMedGoogle Scholar
• Levine MM, Hone D, Tacket C, Ferreccio C, Cryz S. Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as “carrier” vaccines. Res. Microbiol. 141(7–8), 807–816 (1990).
   PubMed Web of Science ®Google Scholar
• Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 8, 129 (2010).
   PubMed Web of Science ®Google Scholar
• Chandran A, Santosham M. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Rev. Vaccines 7(10), 1475–1480 (2008).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338(20), 1405–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. J. Clin. Invest. 100(1), 6–10 (1997).
   PubMed Web of Science ®Google Scholar
• Izadpanah A, Dwinell MB, Eckmann L, Varki NM, Kagnoff MF. Regulated MIP-3alpha/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am. J. Physiol. Gastrointest. Liver Physiol. 280(4), G710–G719 (2001).
   PubMed Web of Science ®Google Scholar
• Fooks AR. Development of oral vaccines for human use. Curr. Opin. Mol. Ther. 2(1), 80–86 (2000).
   PubMedGoogle Scholar
• des Rieux A, Fievez V, Momtaz M et al. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J. Control. Release 118(3), 294–302 (2007).
   PubMed Web of Science ®Google Scholar
• Lazzell V, Waldman RH, Rose C, Khakoo R, Jacknowitz A, Howard S. Immunization against influenza in humans using an oral enteric-coated killed virus vaccine. J. Biol. Stand. 12(3), 315–321 (1984).
   PubMedGoogle Scholar
• Bergmann KC, Waldman RH, Tischner H, Pohl WD. Antibody in tears, saliva and nasal secretions following oral immunization of humans with inactivated influenza virus vaccine. Int. Arch. Allergy Appl. Immunol. 80(1), 107–109 (1986).
   PubMedGoogle Scholar
• Bergmann KC, Waldman RH. Oral immunization with influenza virus: experimental and clinical studies. Curr. Top. Microbiol. Immunol. 146, 83–89 (1989).
   PubMed Web of Science ®Google Scholar
• Avtushenko SS, Sorokin EM, Zoschenkova NY, Zacharova NG, Naichin AN. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization. J. Biotechnol. 44(1–3), 21–28 (1996).
   PubMed Web of Science ®Google Scholar
• Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27(27), 3643–3649 (2009).
   PubMed Web of Science ®Google Scholar
• Pang GT, Clancy RL, O’Reilly SE, Cripps AW. A novel particulate influenza vaccine induces long-term and broad-based immunity in mice after oral immunization. J. Virol. 66(2), 1162–1170 (1992).
   PubMed Web of Science ®Google Scholar
• Takase H, Murakami Y, Endo A, Ikeuchi T. Antibody responses and protection in mice immunized orally against influenza virus. Vaccine 14(17–18), 1651–1656 (1996).
   PubMed Web of Science ®Google Scholar
• Ghazi HO, Potter CW, Smith TL, Jennings R. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs. J. Med. Microbiol. 42(1), 53–61 (1995).
   PubMed Web of Science ®Google Scholar
• Lei H, Xu Y, Chen J, Wei X, Lam DM. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 407(2), 319–324 (2010).
   PubMed Web of Science ®Google Scholar
• Van Daal GJ, Beusenberg FD, So KL et al. Protection against influenza A virus infection in mice by oral immunization with a polyvalent bacterial lysate. Int. J. Immunopharmacol. 13(7), 831–840 (1991).
   PubMed Web of Science ®Google Scholar
• Amorij JP, Westra TA, Hinrichs WL, Huckriede A, Frijlink HW. Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine 26(1), 67–76 (2007).
   PubMed Web of Science ®Google Scholar
• McGhee JR, Yamamoto M, Kang DW et al. Isotype of anti-SIV responses in infected rhesus macaques and in animals immunized by mucosal routes. AIDS Res. Hum. Retroviruses 8(8), 1389 (1992).
   PubMed Web of Science ®Google Scholar
• Waldman RH, Bergmann KC, Stone J et al. Age-dependent antibody response in mice and humans following oral influenza immunization. J. Clin. Immunol. 7(4), 327–332 (1987).
   PubMed Web of Science ®Google Scholar
• Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21(23), 3212–3218 (2003).
   PubMed Web of Science ®Google Scholar
• Wang BZ, Xu R, Quan FS, Kang SM, Wang L, Compans RW. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE 5(11), e13972 (2010).
   PubMed Web of Science ®Google Scholar
• Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75(11), 5141–5150 (2001).
   PubMed Web of Science ®Google Scholar
• Perrone LA, Ahmad A, Veguilla V et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 83(11), 5726–5734 (2009).
   PubMed Web of Science ®Google Scholar
• Quan FS, Compans RW, Kang SM. Oral vaccination with inactivated influenza vaccine induces cross-protective immunity. Vaccine 30(2), 180–188 (2012).
   PubMed Web of Science ®Google Scholar
• Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173(3), 1978–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82(3), 1350–1359 (2008).
   PubMed Web of Science ®Google Scholar
• Mazanec MB, Lamm ME, Lyn D, Portner A, Nedrud JG. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus Res. 23(1–2), 1–12 (1992).
   PubMed Web of Science ®Google Scholar
• Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur. J. Immunol. 14(4), 350–356 (1984).
   PubMed Web of Science ®Google Scholar
• Alsharifi M, Furuya Y, Bowden TR et al. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS ONE 4(4), e5336 (2009).
   Web of Science ®Google Scholar
• Waldman RH, Mann JJ, Small PA Jr. Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. JAMA 207(3), 520–524 (1969).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18(22), 2416–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Boyce TG, Hsu HH, Sannella EC et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19(2–3), 217–226 (2000).
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79(5), 2910–2919 (2005).
   PubMed Web of Science ®Google Scholar
• Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 21(13–14), 1455–1465 (2003).
   PubMed Web of Science ®Google Scholar
• Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2(2), 285–293 (2003).
   PubMedGoogle Scholar
• Jertborn M, Nordström I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun. 69(6), 4125–4128 (2001).
   PubMed Web of Science ®Google Scholar
• Wassén L, Schön K, Holmgren J, Jertborn M, Lycke N. Local intravaginal vaccination of the female genital tract. Scand. J. Immunol. 44(4), 408–414 (1996).
   PubMed Web of Science ®Google Scholar
• Glück R, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181(3), 1129–1132 (2000).
   PubMed Web of Science ®Google Scholar
• Gluck R. Review of intranasal influenza vaccine. Adv. Drug Deliv. Rev. 51(1–3), 203–211 (2001).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med. 350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Dhere R, Yeolekar L, Kulkarni P et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 29(Suppl. 1), A16–A21 (2011).
   PubMed Web of Science ®Google Scholar
• Xie H, Liu TM, Lu X et al. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice. J. Infect. Dis. 200(12), 1874–1883 (2009).
   PubMed Web of Science ®Google Scholar
• Suguitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3(9), e360 (2006).
   PubMed Web of Science ®Google Scholar
• Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23(2), 138–144 (2004).
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 30(5), 886–892 (2012).
   PubMed Web of Science ®Google Scholar
• Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20(9–10), 1340–1353 (2002).
   PubMed Web of Science ®Google Scholar
• Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71(12), 1591–1622 (2011).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Uyeki TM, Broder K et al.; CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. Recomm. Rep. 59(RR-8), 1–62 (2010).
   PubMedGoogle Scholar
• Treanor J, Nolan C, O’Brien D et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24(3), 254–262 (2006).
   PubMed Web of Science ®Google Scholar
• Plante M, Jones T, Allard F et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 20(1–2), 218–225 (2001).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(4 Suppl.), S45–S53 (2005).
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Prins JB, Hoogsteden HC. Lung dendritic cells and host immunity to infection. Eur. Respir. J. 18(4), 692–704 (2001).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Mucosal immunity: implications for vaccine development. Immunobiology 184(2–3), 157–179 (1992).
   PubMed Web of Science ®Google Scholar
• Waldman RH, Wood SH, Torres EJ, Small PA Jr. Influenza antibody response following aerosal administration of inactivated virus. Am. J. Epidemiol. 91(6), 574–585 (1970).
   PubMed Web of Science ®Google Scholar
• Waldman RH, Bond JO, Levitt LP et al. An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull. World Health Organ. 41(3), 543–548 (1969).
   PubMed Web of Science ®Google Scholar
• Wee JL, Scheerlinck JP, Snibson KJ et al. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol. 1(6), 489–496 (2008).
   PubMed Web of Science ®Google Scholar
• Vujanic A, Snibson KJ, Wee JL et al. Long-term antibody and immune memory response induced by pulmonary delivery of influenza Iscomatrix vaccine. Clin. Vaccine Immunol. 19(1), 79–83 (2011).
   PubMedGoogle Scholar
• Vujanic A, Wee JL, Snibson KJ et al. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. Vaccine 28(14), 2593–2597 (2010).
   PubMed Web of Science ®Google Scholar
• Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, Vanbever R. The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 122(3), 316–325 (2007).
   PubMed Web of Science ®Google Scholar
• Smith JH, Nagy T, Barber J, Brooks P, Tompkins SM, Tripp RA. Aerosol inoculation with a sub-lethal influenza virus leads to exacerbated morbidity and pulmonary disease pathogenesis. Viral Immunol. 24(2), 131–142 (2011).
   PubMed Web of Science ®Google Scholar
• Pena L, Vincent AL, Ye J et al. Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses. J. Virol. 85(1), 456–469 (2011).
   PubMed Web of Science ®Google Scholar
• Quan FS, Yoo DG, Song JM, Clements JD, Compans RW, Kang SM. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J. Virol. 83(9), 4489–4497 (2009).
   PubMed Web of Science ®Google Scholar
• Weldon WC, Martin MP, Zarnitsyn V et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin. Vaccine Immunol. 18(4), 647–654 (2011).
   PubMed Web of Science ®Google Scholar
• D’Souza B, Bhowmik T, Shashidharamurthy R, Oettinger C, Selvaraj P, D’Souza M. Oral microparticulate vaccine for melanoma using M-cell targeting. J. Drug Target. 20(2), 166–173 (2012).
   PubMed Web of Science ®Google Scholar
• Lidbury BA, Grissell TV, Sizer PJ, Pang GT, Clancy R, Cripps AW. Erythrocytes enhance the immunogenicity of oral vaccination with gamma irradiated influenza virus: increasing the dose of irradiation results in a significant diminution of lung IgA response. Vaccine 15(14), 1529–1537 (1997).
   PubMed Web of Science ®Google Scholar
• Sendi P, Locher R, Bucheli B, Battegay M. Intranasal influenza vaccine in a working population. Clin. Infect. Dis. 38(7), 974–980 (2004).
   PubMed Web of Science ®Google Scholar
• Sendi P, Locher R, Bucheli B, Battegay M. The decision to get vaccinated against influenza. Am. J. Med. 116(12), 856–858 (2004).
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Campbell DJ, Butcher EC. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 10(3–4), 313–323 (2003).
   PubMed Web of Science ®Google Scholar